{
    "clinical_study": {
        "@rank": "13087", 
        "acronym": "ARENA", 
        "arm_group": [
            {
                "arm_group_label": "Aspirin 75mg", 
                "arm_group_type": "Active Comparator", 
                "description": "Aspirin 75mg once daily for 7 days. Administered by mouth."
            }, 
            {
                "arm_group_label": "Aspirin 1200mg", 
                "arm_group_type": "Active Comparator", 
                "description": "Asprin 600mg twice daily for 7 days. Administered by mouth."
            }, 
            {
                "arm_group_label": "Lactose powder", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo for 7 days. Administered by mouth."
            }
        ], 
        "brief_summary": {
            "textblock": "This is a double-blind, placebo-controled, randomized trial to investigate if aspirin\n      pre-treatment has anti-inflammatory effects in a model of acute lung injury induced by\n      inhaled endotoxin (LPS) in healthy human volunteers."
        }, 
        "brief_title": "The Effect of Aspirin on REducing iNflammation in Human in Vivo Model of Acute Lung Injury", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Acute Lung Injury", 
        "condition_browse": {
            "mesh_term": [
                "Inflammation", 
                "Acute Lung Injury", 
                "Respiratory Distress Syndrome, Adult", 
                "Lung Injury", 
                "Wounds and Injuries"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy non-smoking subjects\n\n        Exclusion Criteria:\n\n          -  Age < 18 years\n\n          -  Pregnancy or breast feeding or woman of childbearing potential not using\n\n          -  adequate contraception.\n\n          -  Participation in a clinical trial of an investigational medicinal product within 30\n             days\n\n          -  Consent declined Aspirin or non steroidal anti-inflammatory (NSAID) use in the past 4\n             weeks\n\n          -  History of asthma\n\n          -  Known aspirin or NSAID hypersensitivity\n\n          -  History of peptic ulcer disease\n\n          -  Platelet count < 150 x 106/ml\n\n          -  Aspirin resistance"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "33", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 4, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01659307", 
            "org_study_id": "11127DMcA-AS", 
            "secondary_id": "2012-001589-13"
        }, 
        "intervention": [
            {
                "arm_group_label": "Aspirin 75mg", 
                "description": "Subjects randomised to aspirin 75mg will receive 1 container containing aspirin 75mg and 1 container containing placebo for the morning and 2 containers containing placebo for the evening. Subjects will take one capsule from each container in the morning and one capsule from each container in the evening.", 
                "intervention_name": "Aspirin 75mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Lactose powder", 
                "description": "Subjects randomised to placebo will receive 4 containers of placebo, 2 containers containing placebo for the morning and 2 containers containing placebo for the evening. Subjects will take one capsule from each container in the morning and one capsule from each container in the evening.", 
                "intervention_name": "Lactose powder", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Aspirin 1200mg", 
                "description": "Subjects randomised to aspirin 600mg 12 hourly will receive 2 containers of aspirin 300mg each for the morning and 2 containers of aspirin 300mg each for the evening. Subjects will take one capsule from each container in the morning and one capsule from each container in the evening.", 
                "intervention_name": "Aspirin 1200mg", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Aspirin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Acute Lung Injury", 
            "Acute Respiratory Distress Syndrome", 
            "Aspirin"
        ], 
        "lastchanged_date": "April 23, 2013", 
        "location": {
            "contact": {
                "email": "d.f.mcauley@qub.a.uk", 
                "last_name": "Danny McAuley", 
                "phone": "+442890 972144"
            }, 
            "facility": {
                "address": {
                    "city": "Belfast", 
                    "country": "United Kingdom"
                }, 
                "name": "Belfast Health and Social Care Trust"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "3", 
        "official_title": "The Effect of Aspirin on REducing iNflammation in Human in Vivo Model of Acute Lung Injury", 
        "overall_contact": {
            "email": "d.f.mcauley@qub.ac.uk", 
            "last_name": "Danny McAuley", 
            "phone": "+442890 972144"
        }, 
        "overall_official": {
            "affiliation": "Queens University, Belfast", 
            "last_name": "Danny McAuley", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United Kingdom: The Belfast Health and Social Care Trust", 
                "United Kingdom: Office for Research Ethics Committees Northern Ireland", 
                "United Kingdom: Medicine and Healthcare products Regulatory Agency", 
                "United Kingdom: Queen's University Belfast"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Bronchoalveolar lavage IL-8 concentration", 
            "safety_issue": "No", 
            "time_frame": "6 hrs after LPS inhalation"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01659307"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Belfast Health and Social Care Trust", 
            "investigator_full_name": "Professor Danny McAuley", 
            "investigator_title": "Professor of Intensive care Medicine", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Alveolar inflammatory response biomarkers", 
                "safety_issue": "No", 
                "time_frame": "6 hrs after LPS inhalation"
            }, 
            {
                "measure": "Plasma inflammatory response biomarkers", 
                "safety_issue": "No", 
                "time_frame": "6 and 24 hrs after LPS inhalation"
            }, 
            {
                "measure": "Alveolar epithelial and endothelial function and injury biomarkers", 
                "safety_issue": "No", 
                "time_frame": "6 hrs after LPS inhalation"
            }, 
            {
                "measure": "Lipid inflammatory mediators", 
                "safety_issue": "No", 
                "time_frame": "6 and 24 hrs after LPS inhalation"
            }
        ], 
        "source": "Belfast Health and Social Care Trust", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "United Kingdom Intensive Care Society", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Northern Ireland Clinical Research Support Centre", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Queen's University, Belfast", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Belfast Health and Social Care Trust", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}